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Abstract
Background: The pathophysiology of chronic fatigue syndrome (CFS) in adolescents is unknown, and the clinical
course and prognosis is still questioned. Recent research indicates that abnormalities of autonomic cardiovascular
control may play an important role. The aim of this research project was to perform a follow-up study of
adolescents with chronic fatigue syndrome, focusing on clinical symptoms and autonomic cardiovascular control.
Methods: 47 adolescents (12-18 years old) with CFS were recruited from the outpatient clinic at the Department
of Pediatrics, Oslo University Hospital. In a primary visit and a follow-up visit (3-17 months later), we evaluated: a) a
wide range of complaints and symptoms and b) cardiovascular variables at baseline and during a 20° head-up tilt-
test (HUT).
Results: At the second visit, patients reported significant improvement regarding functional impairments, fatigue
severity, muscular pain, concentration problems, post-exertional malaise and the problem of non-relieving rest.
Also, at the second visit, baseline heart rate (HR), blood pressure, total peripheral resistance index (TPRI) and LF/HF
(low-frequency:high-frequency heart rate variability ratio, an index of sinus node sympathovagal balance derived
from spectral analyses of heart rate) were significant lower, and the increases in HR, mean blood pressure (MBP),
diastolic blood pressure (DBP) and TPRI during tilt were significantly less pronounced as compared to the first visit.
There was a significant correlation between changes in autonomic symptom score, fatigue severity score and
functional impairment score from the first to the second visit.
Conclusions: The majority of adolescents with CFS experienced an improvement over time in functional
impairment, self-reported fatigue and additional symptoms, and a concurrent improvement of autonomic
cardiovascular control. A possible connection between clinical symptoms and abnormal autonomic control in CFS
might represent a focus for further research.
Keywords: Chronic fatigue syndrome, Fatigue severity scale, Autonomic symptom profile, Cardiovascular auto-
nomic control, Adolescents
Chronic fatigue syndrome (CFS) is a disabling condition,
seriously affecting school-attendance and social activities
[1]. The prevalence among 8-17 year olds has been
reported as high as 1.3% [2]; thus, CFS constitutes a
substantial health problem in adolescence.
Patients with CFS frequently report complaints like
nausea, lightheadedness and photophobia, symptoms
indicative of disturbances in autonomic nervous activity.
Experimental studies have demonstrated distinct
abnormalities in cardiovascular autonomic control [3-5].
Previous reports from our institution have documented
higher blood pressure, heart rate and LF/HF at rest
among adolescent CFS patients as compared to healthy
controls, and a stronger increase of these variables upon
orthostatic stress [6-9]. Similarly, ambulatory measure-
ments of blood pressure and heart rate indicate higher
nocturnal values among CFS patients as compared to
controls [10]. Taken together, these studies suggest that
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an important aspect of CFS pathophysiology [11,12].
Several reports indicate a complete or near complete
recovery in one third of patients; a similar number
experienced no improvement [13-16]. However, the
course of the broad spectrum of symptoms and com-
plaints in adolescent CFS is poorly investigated; this is
particularly true for symptoms of disturbances in auto-
nomic nervous system activity. Likewise, to our knowl-
edge, there is no study exploring the change in
cardiovascular autonomic control over time.
The aim of this study was to explore the parallel
course of clinical symptoms and abnormalities in auto-
nomic cardiovascular control in adolescent CFS patients.
We hypothesized an improvement of all variables with
time, and a positive correlation between changes in fati-
gue, haemodynamics and functional impairments.
Patients and methods
Patients
During the study period from August 2007 to April
2009, adolescent CFS patients aged 12-18 years were
recruited from the Paediatric outpatient clinic, Oslo
University Hospital, Rikshospitalet, Norway, which
serves as a national referral center for children and ado-
lescents with unexplained chronic fatigue. Prior to refer-
ral, they had been tentatively given the diagnosis CFS at
local hospitals.
Different case definitions of CFS exist. The frequently
used definition from the International Chronic Fatigue
Syndrome Study Group (commonly referred to as the
Fukuda-definition) requires at least six months of unex-
plained chronic or relapsing fatigue of new onset,
severely affecting daily activities, as well as four or more
of eight specific accompanying symptoms (headache,
muscle pain, joint pain, sore throat, tender lymph nodes,
impaired memory or concentration, unrefreshing sleep,
and malaise after exertion) [17]. The validity of this defi-
nition has been questioned in adults [18] and children
[19]. Therefore, in this study, the inclusion criterion was
three or more consecutive months of unexplained dis-
abling fatigue worsened by physical or mental exertion.
No other accompanying symptoms were required for
inclusion. This approach is in line with the clinical
recommendations from The Royal College of Paediatrics
and Child Health [1] and the National Institute for
Health and Clinical Excellence [20], and was also proven
feasible in previous studies from our group [6-10]
Generally, no kind of treatment had been established
prior to referral. At our institution, other disease states
that might explain their present symptoms, such as
autoimmune, endocrine, neurologic or psychiatric disor-
ders (including depression), were ruled out by a thor-
ough and standardized set of investigations.
Approximately 50% of the referred patients were diag-
nosed as having CFS according to the criterion specified
above, and were thus eligible for this study. All patients
were given advice about activity adjustment and cogni-
tive behavioral therapy in line with internationally
accepted guidelines [20], whereas the establishment of
treatment and rehabilitation programs was entrusted to
local health service providers.
Study protocol
CFS patients were invited to an experimental session
(consisting of head-up tilt-test (HUT) and a question-
naire) at our institution at the time of their first clinical
visit, and summoned for a second session 3-17 months
later. One week prior to the experiments, all participants
were instructed not to drink beverages containing alco-
hol or caffeine, not to take any drugs, and not to use
tobacco products. Written, informed consent was
obtained from all participants and their parents. The
study was approved by the Regional committee for
ethics in medical research.
Questionnaire
Items from the Autonomic Symptom Profile (ASP) [21]
and the Fatigue Severity Scale (FSS) [22], which are vali-
dated instruments for assessing autonomic dysfunction
and fatigue, respectively, were translated into Norwegian
by one of the authors (VBW) and slightly modified in
order to fit our particular age group. The modified ASP
consists of 22 items addressing orthostatic intolerance,
vasomotor symptoms, sudomotor symptoms, gastroin-
testinal function, eye reflexes and sleep problems; the
response alternatives are partly dichotomous ("yes” and
“no”) and partly 1-5 Likert scale. The modified FSS con-
sists of 7 items having a 1-5 Likert scale. In addition to
these instruments, we added items addressing common
CFS symptoms (such as problems of concentration and
memory) and functional impairments (such as school
absenteeism), all answered on 1-5 Likert scales. The
questionnaire has proven feasible in previous studies
from our institution [7,8].
Patients were also interviewed regarding therapeutic
interventions during the period between the first and
second experimental session.
Head-up tilt-test (HUT)
HUT was undertaken according to a revised protocol
established by Wyller et al. [8]. The feasibility of this
protocol for studying adolescent CFS patients has been
demonstrated in several previous studies [6,8]. In parti-
cular, the low tilt angle (20°) does not normally precipi-
tate syncope, which is otherwise a common problem
among adolescents being subjected to stronger ortho-
static challenges [23]. Still, a 20° head-up tilt is sufficient
Sulheim et al. BioPsychoSocial Medicine 2012, 6:10
http://www.bpsmedicine.com/content/6/1/10
Page 2 of 8to demonstrate hemodynamic alterations among CFS
patients compared to healthy controls.
HUT was performed at daytime between 8 a.m. and 3
p.m. under calm conditions, dimmed lights and a stable
room- temperature of 23-25°C. Patients were attached
to the Task Force Monitor
® (Model 3040i, CNSystems
Medizintechnic, Graz, Austria); a combined hardware
and software device for noninvasive continuous record-
ing of cardiovascular variables [24]. They were posi-
tioned horizontally on a tilt-table with foot-board
support (Model 900-00, CNS-systems Medizintechnik,
Graz, Austria), with a safety strap over the waist. After 5
minutes of baseline recordings, they were head-up tilted
20° for 15 minutes, followed by another 5 minute epoch
in a horizontal position. Subjects did not speak and
were not spoken to.
Instantaneous heart rate (HR) was obtained from the R-
R interval of the electrocardiogram. Photoplethysmogra-
phy on the right middle finger was used to obtain a non-
invasive, continuous recording of arterial blood pressure.
This method correlates satisfactorily with invasive pressure
measurements [25], and has been validated in adolescents
and children [26]. Impedance cardiography was used to
obtain a continuous recording of the temporal derivate of
the transthoracic impedance (dZ/dt) [27].
All recorded signals were on-line transferred to the
built-in recording computer of the Task Force Monitor
®,
running software for real-time data acquisition. Beat-to-
beat mean arterial blood pressure (MBP) was calculated
by numerical integration of the recorded instantaneous
blood pressure signal. Beat-to-beat stroke volume (SV)
was calculated from the impedance signal [24,28]. This
method has been validated both in adults [29] and chil-
dren [30]. The RR-interval from the heart rate recording
was subjected to spectral analysis using an adaptive auto-
regressive algorithm, creating a time-varying spectrum
[31]. Spectral power densities (absolute values) were cal-
culated in the low-frequency (LF) band (0.04-0.15 Hz)
and the high-frequency (HF) band (0.15-0.4 Hz); we also
calculated the LF/HF. These indices are measures of
autonomic heart rate control;t h eL F / H Fi sam e a s u r eo f
“sympathovagal balance”, where higher values indicate
enhanced sympathetic activity [32].
Data analysis
Questionnaire data were exported to Microsoft Excel for
further analyses. The answers to all ASP items were
dichotomized and given the value 0 (symptom not/rarely
present) or 1 (symptom often/always present). An Auto-
nomic symptom score was then defined as the sum
across all ASP items, having a total range from 0 to 22.
A Fatigue severity score was created by taking the arith-
metical mean across all 7 items from FSS; total range is
from 0 to 5. Likewise, a Functional impairment score
was defined as the arithmetical mean across three items
addressing, respectively, school absenteeism, leisure
activities and being with friends on a 1-5 Likert scale;
thus, total range is from 1 to 5.
The HUT data from the Task Force Monitor was
exported to Microsoft Excel for further analysis. From
each experimental run of HUT, we calculated the med-
ian of all variables in two epochs: From 270 to 30 sec-
onds prior to tilt (Baseline) and from 300 to 540
seconds after being tilted (Tilt). We also computed delta
values (Tilt–Baseline). Beat-to-beat total peripheral
resistance index (TPRI) was calculated as MBP divided
by the product of SV and HR, and then indexed against
body surface area (BSA) [33]. This method of analyzing
results from HUT has successfully been used in previous
projects from our institution [6,8].
Statistical analyses were carried out using SPSS statistical
software (SPSS Inc. Chicago, IL, USA). Inspection of plots
displayed lack of normal distribution for several variables;
consequently, we have used non-parametric statistics: Wil-
coxon signed rank test was applied for comparison of
results from the two visits, whereas Kendall rank correla-
tion was used to explore the relationship between changes
in variables from the first to the second visit. A p-value <
0.05 was considered statistically significant.
Results
During the recruiting period, 47 patients were included
in the study. Six patients refused a second visit and
were lost to follow-up. These patients (3 females and 3
males) were principally equal to the included patients
regarding age, height and weight, fatigue severity score,
and baseline HR and MBP. Of the remaining 41, one
was excluded due to reevaluation of the diagnosis and
two did not answer the questionnaire, leaving 38
patients (30 females, 8 males; 27 fulfilling the Fukuda
definition of CFS) for the final analyses. Demographic
details are given in Table 1.
At the time of the first visit, patients had high Fatigue
severity score, and also a high score on items addressing
other CFS symptoms, such as non-relieving rest, concen-
tration problems and post-exertional malaise (Table 2).
Also, they reported symptoms of orthostatic intolerance
such as lightheadedness, as reflected in the ASP score.
However, symptoms such as sore throat and enlarged lym-
phatic nodes, which both are criteria in the Fukuda defini-
tion of CFS [17], were uncommon among our patients.
During the time span from the first to the second
visit, 27 of the patients had tried one or more therapeu-
tic interventions, such as graded exercise therapy, cogni-
tive behavioral therapy and drugs (propranolol,
fludrocortisone). Treatment intensity and duration var-
ied considerably; thus, estimating effect from each inter-
vention is not feasible.
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ment of mean Fatigue severity score (from 4.7 to 3.9, p
< 0.001) (Table 2). On an individual basis, such
improvement was experienced by 22 (58%) of the
patients, whereas 8 (21%) had unchanged Fatigue sever-
ity score and 8 (21%) had worsened score. Also, the
mean score of the three most prevalent additional symp-
toms (non-relieving rest, concentration problems and
post-exertional malaise) improved significantly as com-
pared to the first visit, as did the Functional impairment
score. Furthermore, there was a significant improvement
of muscular pain.
At the time of the first visit, patients had high HR,
blood pressure, TPRI and LF/HF at baseline and a
strong increase in these variables upon tilt. At the sec-
ond visit, baseline HR, blood pressure, TPRI and LF/HF
were significantly lower and the increase in HR, MBP,
DBP and TPRI during tilt were significantly less pro-
nounced as compared to the first visit (Table 3). Thus,
most of the hemodynamic variables at the second visit
were closer to values observed in healthy controls [6,8].
T h ec h a n g ei nF a t i g u es e v e r i t ys c o r ef r o mt h ef i r s tt o
the second visit was significantly correlated with change
in Autonomic score (Table 4). Also, change in Func-
tional impairment score was significantly correlated with
change in Fatigue severity score.
Discussion
The most important findings of this follow-up study are:
1) An improvement of self-reported fatigue and
other common CFS symptoms.
2) An improvement of hemodynamic responses dur-
ing HUT.
3) Correlations between changes in autonomic
symptom score, fatigue severity score and functional
score.
Improvement of fatigue and other symptoms
FSS is a commonly used, validated tool for measuring
fatigue in various diseases, and has a documented ability
to detect change over time [34,35]. A highly significant
improvement as measured by FSS therefore clearly dis-
plays the clinical improvement of our adolescent patient
Table 1 Subject characteristics
First visit Second
visit
Total number, n 38 38
Participants satisfying the Fukuda definition of
CFS, n (%)
27 (71)
Age (years), median (range) 15 16
(12-18) (13-20)
Length (cm), median (range) 165 166
(146-187) (147-189)
Weight (kg), median (range) 61 61.5
(35-103) (35-94)
BMI (kg/m
2), median (range) 21.2 21.6
(16.5-35.6) (15.6-32.5)
CFS duration (months), median (range) 18.5 31
(9-72) (12-83)
Follow-up time (months), median (range) n.a. 8
(3-17)
BMI = Body mass index; CFS = chronic fatigue syndrome













Non-relieving rest 3.8 3.0 0.005
(1.0-5.0) (1.0-5.0)
Concentration problems 3.7 3.2 0.022
(1.0-5.0) (1.0-5.0)
Post-exertional malaise 3.6 2.6 < 0.001
(1.0-5.0) (1.0-5.0)
Sensitivity towards sounds 3.1 2.6 0.110
(1.0-5.0) (1.0-5.0)
Problems of getting asleep 2.9 3.1 0.621
(1.0-5.0) (1.0-5.0)
Headache 2.8 2.7 0.562
(1.0-5.0) (1.0-5.0)
Muscular pain 2.7 2.2 0.026
(1.0-5.0) (1.0-5.0)
Problems of memory 2.7 2.6 0.715
(1.0-5.0) (1.0-5.0)
Nausea 2.4 2.2 0.267
(1.0-5.0) (1.0-4.0)
Joint pain 2.4 2.1 0.252
(1.0-5.0) (1.0-5.0)
Sore throat 1.7 1.9 0.931
(1.0-5.0) (1.0-4.0)
Enlarged lymphatic nodes 1.5 1.3 0.334
(1.0-5.0) (1.0-3.0)
Autonomic score
a 12.7 12.2 0.436
(8-21) (6-22)
Functional impairment score
b 3.4 2.8 0.003
(2.0-5.0) (1.0-5.0)
Median (range)
§ n varies due to different response rates. * Wilcoxon’s signed rank test, 2-
sided.
† The average of 7 items, each having a 1-5 Likert scale.
‡ Each single
item was scored on a 1-5 Likert scale.
a The sum of 22 dichotomized items
addressing different autonomic symptoms; total range is from 0 to 22.
b The
average of 3 items, each having a 1-5 Likert scale
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by improvement of other symptoms contributing signifi-
cantly to the patients’ disability, as well as a significant
improvement of self-reported functional level.
Improvement of hemodynamic variables during HUT
Altered autonomic nervous activity characterized by
enhanced sympathetic cardiovascular control has been
documented by several CFS researchers [2-10], and
might constitute a key element of CFS pathophysiology
[11]. Indeed, previous experiments from our institution
applying HUT and related techniques did find increased
HR, blood pressure, TPRI and LF/HF at rest, and a
stronger increase in these variables upon orthostatic
challenge in CFS patients as compared to healthy con-
trols [6-9]. In this study, the haemodynamics among
Table 3 Hemodynamic variables at supine rest and during a 20° head-up tilt-test.




Second visit (n = 37) p-value*
Baseline
HR (beats/min) 72.6 67.5 0.033 68.3
(68.9-76.9) (63.5-74.0) (65.5-72.4)
SBP (mm Hg) 108.3 98.9 < 0.001 111.1
(105.2-116.1) (95.3-101.9) (107.9-116.0)
MBP (mm Hg) 80.4 74.0 < 0.001 79.8
(77.1-84.8) (70.5-75.6) (77.2-81.7)
DBP (mm Hg) 68.1 59.3 < 0.001 64.6
(64.9-73.1) (57.5-63.5) (62.8-65.9)
TPRI (mm Hg/l/min/m
2) 8.4 7.2 0.001 7.4
(7.5-9.4) (6.9-8.2) (6.9-7.7)
LF/HF 0.6 0.4 0.017 0.6
(0.4-0.9) (0.4-0.6) (0.4-1.0)
Response (Tilt–Baseline)
Δ HR (beats/min) 5.4 2.3 0.030 0.9
(2.5-6.5) (1.0-3.0) (-0.2-2.2)
Δ SBP (mm Hg) 2.1 1.8 0.531 -0.9
(0.9-3.8) (-0.2-4.0) (-1.8-0.9)
Δ MBP (mm Hg) 4.3 1.6 0.001 0.3
(3.2-6.7) (0.5-3.3) (-1.6-1.7)
Δ DBP (mm Hg) 4.1 1.6 0.001 0.4
(3.6-5.8) (0.3-2.8) (-1.5-2.5)
Δ TPRI (mm Hg/l/min/m
2) 1.0 0.7 < 0.001 0.2
(0.7-1.6) (0.3-0.8) (-0.02-0.5)
Δ LF/HF 0.3 0.2 0.187 -0.03
(0.1-0.5) (0.1-0.3) (-0.2-0.1)
Median (confidence intervals)
* Wilcoxon’s signed rank test, 2-sided, between first and second visits for the CFS patients.
†Although not the primary scope of this article, reference values from
healthy control subjects are displayed for clarity. Details concerning this reference material have been described elsewhere [8]. In order to avoid methodological
problems of multiple comparisons, statistical tests between patients and control subjects have not been carried out
HR = heart rate; SBP = systolic blood pressure; MBP = mean arterial blood pressure; DBP = diastolic blood pressure; TPRI = total peripheral resistance index; LF/
HF = Ratio of low-frequency to high frequency power of heart rate variability
Table 4 Correlation* between changes (first to second visit) of selected variables









Change in Fatigue severity score
† n.a n.a 0.27 0.044
Change in Functional impairment score
b 0.36 0.003 0.14 0.291
* Kendall rank correlation. § Kendall’s tau test, 2-sided.
† The average of 7 items, each having a 1-5 Likert scale.
a The sum of 22 dichotomized items addressing
different autonomic symptoms; total range is from 0 to 22.
b The average of 3 items, each having a 1-5 Likert scale. τ = tau (correlation coefficient)
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observations. However, at the second visit, CFS patients
had significantly lower baseline values for all measured
hemodynamic variables as compared to the fist visit,
indicating a decrease in sympathetic cardiovascular
influence at rest. Furthermore, the changes in hemody-
namic variables during tilt were smaller, indicating a
less pronounced sympathetic cardiovascular influence
during orthostatic challenge. Thus, at the second visit,
the HUT results among CFS patients were closer to
what has previously been reported among healthy ado-
lescents [6,8].
Correlation between changes in autonomic score, fatigue
score and function score
The concomitant improvement of symptoms, HUT-
responses and self-reported functional abilities suggests
a possible causal relation between these variables, in line
with recent theories advocating autonomic abnormalities
as an important part of CFS pathophysiology [11]. The
significant correlation between changes in autonomic
symptoms, fatigue and functional impairment further
strengthens this notion. However, we failed to demon-
strate a statistically significant correlation between
changes in questionnaire variables and changes in HUT-
variables. This might be due to methodological con-
straints (few participants, no normal distribution of vari-
ables). In addition, the relation between symptoms and
certain pathophysiological characteristics might be com-
plex and non-linear, as has recently been suggested for
the subtle alterations of the hypothalamus-pituitary-
adrenal system in CFS [36].
This study was not designed for assessment of causal
relations; for instance, autonomic abnormalities might
cause fatigue, fatigue might give rise to autonomic
abnormalities, or they might both be the product of a
third variable. Further studies should focus on these
questions. If they confirm a pathophysiological role of
altered cardiovascular autonomic control in CFS, this
phenomenon might constitute a possible target for ther-
apeutic interventions, e.g. with pharmaceuticals attenu-
ating sympathetic nervous activity. In addition, the
responses to HUT might emerge as a possible biomar-
ker of the disease processes.
Study limitations
A challenge regarding CFS research is the diversity in
case definition and inclusion criteria. This study applied
a modification of the Fukuda-definition, and our results
cannot be readily compared with studies adhering
strictly to this definition. Of note, our patients had
remarkably low scores on some of the additive criteria
of the Fukuda definition of CFS, in particular sore throat
and tender lymph nodes [17]. This adds to the ongoing
discussion of the validity of this definition [18]; at least,
our findings indicate that a strict application of these
criteria may correspond to a small fraction of all adoles-
cents with long-lasting, unexplained and disabling fati-
gue. Thus, omission of these additive criteria, as applied
in this study and advocated by the guidelines from the
Royal College of Paediatrics and Child Health [1] and
the National Institute for Health and Clinical Excellence
[20], seems to increase the ecological validity and
improves the generalizability of the results towards rou-
tine clinical care
All participants in this study were recruited from a
national referral center, possibly causing a selection bias:
those being less severely affected from CFS might not
have come to our attention. This might shift our results
towards worse outcome regarding the entire adolescent
CFS population. On the other hand, no one was perma-
nently bed-ridden; thus, the most severely affected
patients did not participate in this study.
The questionnaire has not been formally validated.
However, its major components, such as the Fatigue
Severity Scale and The Autonomic Symptom Profile, are
validated instruments; the translated and slightly
adjusted versions of these instruments have proven fea-
sible in previous studies from our institution [7,8].
At the first visit, patients had fasted overnight and all
tests were performed between 8 and 11 a.m. The same
strict regime did not apply to HUT at the second visit.
This might bias our data due to diurnal variation in
HUT responses. However, whereas a recent study by
Brewster and co-workers demonstrated higher HR in
the morning in a group of patients with the postural
orthostatic tachycardia syndrome, no diurnal variations
were found for blood pressure [37].
Only 37 patients were included, but based on experi-
ences from earlier studies at our institution, we had rea-
son to assume that a sample of more than 30 patients
would be sufficient to discover significant and clinically
interesting changes in a follow-up study.
We cannot rule out that the changes in hemodynamic
r e s p o n s e sf r o mt h ef i r s tt ot h es e c o n dv i s i tc o u l db e
partly or totally explained from habituation; i.e., that the
participants were less anxious and uncomfortable at the
second visit. However, this possibility does not explain
the improvement of symptoms. Also, changes in hemo-
dynamic responses could be explained from natural
pubertal development of the patients during the same
period. However, in linear regression analyses, the num-
ber of months between the first and the second visit
was not significantly related to changes in HUT vari-
ables (results not shown).
Finally, some of the patients received different kind of
treatment between the first and second visit. The design
of the study does not allow detailed analyses of the
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Indeed, further studies should explore these relations
within a strictly controlled design.
Concluding remarks
In conclusion, our study shows an improvement over
time in self-reported fatigue and other common CFS-
symptoms, in line with several other studies. Also, we
have demonstrated a concomitant improvement of
hemodynamic variables and functional abilities, support-
ing a theory of autonomic abnormalities as an important
part of CFS pathophysiology. The results call for further
investigation regarding autonomic control in CFS,
research that will, hopefully, reveal pathophysiological
mechanisms that might open new therapeutic options.
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